PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 256 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,140,466 | -29.8% | 102,362 | -8.3% | 0.00% | -33.3% |
| Q2 2023 | $4,470,530 | +245.3% | 111,568 | +251.7% | 0.01% | +200.0% |
| Q1 2023 | $1,294,656 | +189.5% | 31,724 | +173.9% | 0.00% | +100.0% |
| Q4 2022 | $447,220 | -99.9% | 11,583 | -5.0% | 0.00% | 0.0% |
| Q2 2022 | $710,910,000 | -50.9% | 12,194 | -35.7% | 0.00% | -50.0% |
| Q1 2022 | $1,446,417,000 | -18.3% | 18,952 | -35.6% | 0.00% | -33.3% |
| Q4 2021 | $1,771,465,000 | -25.9% | 29,441 | -31.1% | 0.00% | 0.0% |
| Q3 2021 | $2,391,256,000 | +154.9% | 42,701 | +176.1% | 0.00% | +200.0% |
| Q2 2021 | $938,295,000 | +55.9% | 15,463 | +80.0% | 0.00% | 0.0% |
| Q1 2021 | $602,003,000 | +3.9% | 8,589 | -11.3% | 0.00% | 0.0% |
| Q4 2020 | $579,311,000 | -14.9% | 9,681 | -14.5% | 0.00% | 0.0% |
| Q3 2020 | $681,039,000 | +263.4% | 11,328 | +217.1% | 0.00% | – |
| Q2 2020 | $187,423,000 | -97.1% | 3,572 | -98.2% | 0.00% | -100.0% |
| Q1 2020 | $6,536,238,000 | +1317.1% | 194,937 | +1814.5% | 0.01% | +1200.0% |
| Q4 2019 | $461,245,000 | +65.7% | 10,182 | +39.3% | 0.00% | – |
| Q3 2019 | $278,330,000 | +19.3% | 7,311 | +36.3% | 0.00% | – |
| Q2 2019 | $233,324,000 | -33.7% | 5,365 | -42.0% | 0.00% | -100.0% |
| Q1 2019 | $352,131,000 | +751.8% | 9,252 | +862.7% | 0.00% | – |
| Q4 2018 | $41,342,000 | -63.2% | 961 | -57.9% | 0.00% | – |
| Q3 2018 | $112,259,000 | +67.3% | 2,284 | +9.1% | 0.00% | – |
| Q2 2018 | $67,081,000 | -75.1% | 2,093 | -75.8% | 0.00% | -100.0% |
| Q1 2018 | $268,949,000 | -28.7% | 8,634 | +4.6% | 0.00% | 0.0% |
| Q4 2017 | $376,978,000 | +110.8% | 8,258 | +73.4% | 0.00% | – |
| Q3 2017 | $178,851,000 | -25.0% | 4,763 | -4.8% | 0.00% | -100.0% |
| Q2 2017 | $238,595,000 | +610.0% | 5,002 | +578.7% | 0.00% | – |
| Q1 2017 | $33,607,000 | -10.9% | 737 | -36.9% | 0.00% | – |
| Q4 2016 | $37,726,000 | -63.9% | 1,168 | -61.7% | 0.00% | – |
| Q3 2016 | $104,405,000 | +114.4% | 3,051 | +111.3% | 0.00% | – |
| Q2 2016 | $48,706,000 | +3306.0% | 1,444 | +5248.1% | 0.00% | – |
| Q1 2016 | $1,430,000 | -99.7% | 27 | -99.6% | 0.00% | -100.0% |
| Q4 2015 | $542,598,000 | +76.2% | 7,066 | -5.7% | 0.00% | 0.0% |
| Q3 2015 | $307,921,000 | +43.6% | 7,492 | +147.1% | 0.00% | 0.0% |
| Q2 2015 | $214,423,000 | +183.3% | 3,032 | +255.9% | 0.00% | – |
| Q1 2015 | $75,700,000 | -62.7% | 852 | -59.3% | 0.00% | – |
| Q3 2014 | $202,950,000 | +3582.0% | 2,094 | +3390.0% | 0.00% | – |
| Q2 2014 | $5,512,000 | -73.1% | 60 | -83.2% | 0.00% | – |
| Q4 2013 | $20,524,000 | -94.3% | 357 | -95.3% | 0.00% | – |
| Q3 2013 | $362,812,000 | +28.4% | 7,546 | -22.5% | 0.00% | – |
| Q2 2013 | $282,547,000 | – | 9,743 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |